|
ETAA1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.294500000526E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.47870000039619E-07 |
| Normal-vs-Stage2 |
5.00109999967968E-07 |
| Normal-vs-Stage3 |
8.16749999854594E-08 |
| Normal-vs-Stage4 |
9.81790004850325E-09 |
| Stage1-vs-Stage2 |
3.472800E-01 |
| Stage1-vs-Stage3 |
1.780010E-01 |
| Stage1-vs-Stage4 |
2.139600E-02 |
| Stage2-vs-Stage3 |
9.550400E-01 |
| Stage2-vs-Stage4 |
4.313400E-01 |
| Stage3-vs-Stage4 |
3.880200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.62630000156395E-08 |
| Normal-vs-AfricanAmerican |
5.88189999999322E-05 |
| Normal-vs-Asian |
1.58228000000094E-05 |
| Caucasian-vs-AfricanAmerican |
9.894200E-01 |
| Caucasian-vs-Asian |
5.274400E-01 |
| AfricanAmerican-vs-Asian |
6.803000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.59669999946865E-07 |
| Normal-vs-Female |
1.50039999979867E-07 |
| Male-vs-Female |
9.938200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.52549999988506E-07 |
| Normal-vs-Age(41-60Yrs) |
1.33539999946919E-07 |
| Normal-vs-Age(61-80Yrs) |
2.25069999970628E-07 |
| Normal-vs-Age(81-100Yrs) |
7.675600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.244200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.190000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.962400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.681000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.398000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.947800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.408000E-01 |
| Classical-VS-Follicular |
3.544400E-01 |
| Classical-VS-Other |
8.800200E-01 |
| Classical-VS-Normal |
1.2998999999736E-06 |
| Tall-VS-Follicular |
7.416400E-01 |
| Tall-VS-Other |
6.379200E-01 |
| Tall-VS-Normal |
4.44460000026403E-07 |
| Follicular-VS-Other |
8.562200E-01 |
| Follicular-VS-Normal |
3.83639999990137E-07 |
| Other-VS-Normal |
3.979700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.32769999994231E-07 |
| Normal-vs-N1 |
2.58849999990041E-07 |
| N0-vs-N1 |
6.951200E-01 |
|
|
